Contracts › 75N93022C00059
75N93022C00059: Development of Epetraborole As a Novel Therapeutic for Melioidosis and Additional Antimicrobial Resistant (AMR) Bacterial Biothreat Pathogens.
Awarded to An2 Therapeutics, Inc by National Institutes of Health (NIH).
$9.2Mobligated
$18.3Mpotential value
31 July 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93022C00059 |
|---|---|
| Awardee | An2 Therapeutics, Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CA |
| Offers received | 30 |
| Period of performance | 20 September 2022 to 31 July 2027 |
| Potential end | 31 July 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record